Dominique Guerrot

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/5245288/publications.pdf

Version: 2024-02-01

95 papers	3,031 citations	186265 28 h-index	182427 51 g-index
127 all docs	127 docs citations	127 times ranked	4491 citing authors

#	Article	IF	Citations
1	Vaptans or voluntary increased hydration to protect the kidney: how do they compare?. Nephrology Dialysis Transplantation, 2023, 38, 562-574.	0.7	3
2	Belatacept rescue conversion in kidney transplant recipients with vascular lesions (Banff cv) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 702 T	0.7	4
3	Immunoglobulin A nephropathy in association with inflammatory bowel diseases: results from a national study and systematic literature review. Nephrology Dialysis Transplantation, 2022, 37, 531-539.	0.7	10
4	Kidney Transplant T Cellâ€“Mediated Rejection Occurring After Anti-CD19 CAR T-Cell Therapy for Refractory Aggressive Burkitt-like Lymphoma With 11q Aberration: A Case Report. American Journal of Kidney Diseases, 2022, 79, 760-764.	1.9	15
5	Kidney Histopathology Can Predict Kidney Function in ANCA-Associated Vasculitides with Acute Kidney Injury Treated with Plasma Exchanges. Journal of the American Society of Nephrology: JASN, 2022, 33, 628-637.	6.1	24
6	CD86 occupancy in belataceptâ€treated kidney transplant patients is not associated with clinical and infectious outcomes. American Journal of Transplantation, 2022, , .	4.7	2
7	Idiopathic nephrotic syndrome relapse following COVID-19 vaccination: a series of 25 cases. CKJ: Clinical Kidney Journal, 2022, 15, 1574-1582.	2.9	7
8	Efficacy of antiâ€“SARS-CoV-2 monoclonal antibody prophylaxis and vaccination on the Omicron variant of COVID-19 in kidney transplant recipients. Kidney International, 2022, 102, 440-442.	5.2	36
9	T cell and antibody responses to SARS-CoV-2: Experience from a French transplantation and hemodialysis center during the COVID-19 pandemic. American Journal of Transplantation, 2021, 21, 854-863.	4.7	36
10	Preservation of epoxyeicosatrienoic acid bioavailability prevents renal allograft dysfunction and cardiovascular alterations in kidney transplant recipients. Scientific Reports, 2021, 11, 3739.	3.3	4
11	Kidney and contrast media: Common viewpoint of the French Nephrology societies (SFNDT, FIRN, CJN) and the French Radiological Society (SFR) following ESUR guidelines. Diagnostic and Interventional Imaging, 2021, 102, 131-139.	3.2	14
12	Intensity of de novo DSA detected by Immucor Lifecodes assay and C3d fixing antibodies are not predictive of subclinical ABMR after Kidney Transplantation. PLoS ONE, 2021, 16, e0249934.	2.5	2
13	Tweet me: conferencing in the era of COVID-19 and 280 characters. CKJ: Clinical Kidney Journal, 2021, 14, 2142-2150.	2.9	3
14	Is intraoperative heparin during renal transplantation useful to reduce graft vascular thrombosis?. Progres En Urologie, 2021, 31, 531-538.	0.8	2
15	Antibody and T Cell Response to SARS-CoV-2 Messenger RNA BNT162b2 Vaccine in Kidney Transplant Recipients and Hemodialysis Patients. Journal of the American Society of Nephrology: JASN, 2021, 32, 2147-2152.	6.1	155
16	Switch from calcineurin inhibitors to belatacept in kidney transplant patients with chronic-active antibody mediated rejection results in lower decline in kidney function at three years. Journal of Nephrology, 2021, 34, 2159-2162.	2.0	1
17	Antibody response to SARS-CoV-2 mRNA BNT162b2 vaccine in kidney transplant recipientsÂand in-centre and satellite centre haemodialysis patients. CKJ: Clinical Kidney Journal, 2021, 14, 2127-2128.	2.9	10
18	Eculizumab in gemcitabine-induced thrombotic microangiopathy: experience of the French thrombotic microangiopathies reference centre. BMC Nephrology, 2021, 22, 267.	1.8	24

#	Article	IF	Citations
19	Antibody and T-cell response to a third dose of SARS-CoV-2 mRNA BNT162b2 vaccine in kidney transplant recipients. Kidney International, 2021, 100, 1337-1340.	5.2	46
20	SARS-CoV-2â€“specific Humoral and Cellular Immunities in Kidney Transplant Recipients and Dialyzed Patients Recovered From Severe and Nonsevere COVID-19. Transplantation Direct, 2021, 7, e792.	1.6	8
21	Protocol Biopsies in Patients With Subclinical De Novo Donor-specific Antibodies After Kidney Transplantation: A Multicentric Study. Transplantation, 2020, 104, 1726-1737.	1.0	25
22	Low incidence of SARS-CoV-2, risk factors of mortality and the course of illness in the French national cohort of dialysis patients. Kidney International, 2020, 98, 1519-1529.	5.2	103
23	Organ Transplantation in Hereditary Fibrinogen A Î±-Chain Amyloidosis: A Case Series of French Patients. American Journal of Kidney Diseases, 2020, 76, 384-391.	1.9	5
24	Severe Infection in Anti-Glomerular Basement Membrane Disease: A Retrospective Multicenter French Study. Journal of Clinical Medicine, 2020, 9, 698.	2.4	5
25	Opportunistic infections after conversion to belatacept in kidney transplantation. Nephrology Dialysis Transplantation, 2020, 35, 336-345.	0.7	54
26	5/6 nephrectomy induces different renal, cardiac and vascular consequences in 129/Sv and C57BL/6JRj mice. Scientific Reports, 2020, 10, 1524.	3.3	34
27	Adrenocortical carcinoma complicated by renal thrombotic microangiopathy, a case-series. BMC Nephrology, 2020, 21, 35.	1.8	5
28	Soluble Epoxide Hydrolase Inhibition Prevents Experimental Type 4 Cardiorenal Syndrome. Frontiers in Molecular Biosciences, 2020, 7, 604042.	3.5	2
29	Hemolysis induced by Left Ventricular Assist Device is associated with proximal tubulopathy. PLoS ONE, 2020, 15, e0242931.	2.5	5
30	Blood pressure targets in chronic kidney disease. Current Opinion in Nephrology and Hypertension, 2020, 29, 327-332.	2.0	5
31	Long-term Outcomes after Transplant Renal Artery Stenosis Surgery. Annals of Vascular Surgery, 2019, 54, 261-268.	0.9	5
32	Ipilimumab-induced renal granulomatous arteritis: a case report. BMC Nephrology, 2019, 20, 366.	1.8	11
33	Risk Factors for Early Graft Failure andÂDeath After Kidney Transplantation inÂRecipients Older Than 70 Years. Kidney International Reports, 2019, 4, 656-666.	0.8	44
34	Nonâ€proteinuric renal al amyloidosis in waldenstrÃ¶m's macroglobulinemia. Nephrology, 2019, 24, 490-491.	1.6	0
35	Comparison of Two Luminex Single-antigen Bead Flow Cytometry Assays for Detection of Donor-specific Antibodies After Renal Transplantation. Transplantation, 2019, 103, 597-603.	1.0	26
36	Endothelium structure and function in kidney health and disease. Nature Reviews Nephrology, 2019, 15, 87-108.	9.6	292

#	Article	IF	Citations
37	Diagnostic Value of Flexible Bronchoscopy in kidney transplant recipients. , 2019, , .		0
38	Monoclonal B lymphocytosis and minimal change disease: a new monoclonal B-cell disorder of renal significance?. Journal of Nephrology, 2018, 31, 317-320.	2.0	3
39	Efficacy and Safety of Rituximab in Hepatitis B Virusâ€“Associated PLA2R-Positive Membranous Nephropathy. Kidney International Reports, 2018, 3, 486-491.	0.8	25
40	Population Pharmacokinetic-Pharmacodynamic Modeling of Ropivacaine in Spinal Anesthesia. Clinical Pharmacokinetics, 2018, 57, 1135-1147.	3.5	24
41	Early predictors of one-year mortality in patients over 65 presenting with ANCA-associated renal vasculitis: a retrospective, multicentre study. BMC Nephrology, 2018, 19, 317.	1.8	34
42	An open-label randomized controlled trial of low-dose corticosteroid plus enteric-coated mycophenolate sodium versus standard corticosteroid treatment for minimal change nephrotic syndrome in adults (MSN Study). Kidney International, 2018, 94, 1217-1226.	5.2	20
43	Both Monoclonal and Polyclonal Immunoglobulin Contingents Mediate Complement Activation in Monoclonal Gammopathy Associated-C3 Glomerulopathy. Frontiers in Immunology, 2018, 9, 2260.	4.8	42
44	Cobalamin C Deficiency Induces a Typical Histopathological Pattern of Renal Arteriolar and Glomerular Thrombotic Microangiopathy. Kidney International Reports, 2018, 3, 1153-1162.	0.8	28
45	Antithymocyte globulin-induced hemolytic anemia and thrombocytopenia after kidney transplantation. Immunotherapy, 2018, 10, 737-742.	2.0	5
46	Protein tyrosine phosphatase 1B inactivation limits aging-associated heart failure in mice. American Journal of Physiology - Heart and Circulatory Physiology, 2018, 314, H1279-H1288.	3.2	11
47	von BrÃ¼nn Nests Hyperplasia as a Cause ofÂUreteral Stenosis After Kidney Transplantation. Kidney International Reports, 2017, 2, 498-501.	0.8	1
48	Kidney transplantation in patients with systemic sclerosis: a nationwide multicentre study. Transplant International, 2017, 30, 256-265.	1.6	30
49	Clinical features and prognostic factors of listeriosis: the MONALISA national prospective cohort study. Lancet Infectious Diseases, The, 2017, 17, 510-519.	9.1	366
50	Treatment of B-cell disorder improves renal outcome of patients with monoclonal gammopathyâ€“associated C3 glomerulopathy. Blood, 2017, 129, 1437-1447.	1.4	120
51	Osteonecrosis of the Jaw in a Patient Presenting With Post-Transplantation Lymphoproliferative Disorder Treated With Rituximab: A Case Report. Journal of Oral and Maxillofacial Surgery, 2017, 75, 2599-2605.	1.2	15
52	Belatacept Rescue Therapy in Kidney Transplant Recipients With Vascular Lesions: A Case Control Study. American Journal of Transplantation, 2017, 17, 2937-2944.	4.7	17
53	Clinical Value of Natriuretic Peptides in Predicting Time to Dialysis in Stage 4 and 5 Chronic Kidney Disease Patients. PLoS ONE, 2016, 11, e0159914.	2.5	12
54	Belatacept and Long-Term Outcomes in Kidney Transplantation. New England Journal of Medicine, 2016, 374, 2598-2601.	27.0	38

#	Article	IF	Citations
55	The Use of Ferritin to Identify Critically Ill Patients With Secondary Hemophagocytic Lymphohistiocytosis*. Critical Care Medicine, 2016, 44, e1045-e1053.	0.9	40
56	0376 : Impact of the inhibition of soluble epoxide hydrolase on cardiovascular consequences of chronic kidney disease. Archives of Cardiovascular Diseases Supplements, 2016, 8, 233.	0.0	0
57	Long term outcome of patients with low level of cryoglobulin (<0.05g/L). Autoimmunity Reviews, 2016, 15, 440-446.	5.8	10
58	Impact of the inhibition of soluble epoxide hydrolase on cardiovascular consequences of chronic kidney disease. Nephrologie Et Therapeutique, 2016, 12, 412.	0.5	0
59	[OP.4D.03] IMPACT OF THE INHIBITION OF SOLUBLE EPOXIDE HYDROLASE ON CARDIOVASCULAR CONSEQUENCES OF CHRONIC KIDNEY DISEASE. Journal of Hypertension, 2016, 34, e51.	0.5	0
60	Efficacy of Eculizumab in Gemcitabine-Induced Thrombotic Microangiopathy: Experience of the French Thrombotic Microangiopathies Reference Centre. Blood, 2016, 128, 136-136.	1.4	7
61	Immune Reconstitution Inflammatory Syndrome Secondary toMycobacterium kansasiiInfection in a Kidney Transplant Recipient. American Journal of Transplantation, 2015, 15, 3255-3258.	4.7	15
62	The Spectrum of Kidney Pathology in B-Cell Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma: A 25-Year Multicenter Experience. PLoS ONE, 2015, 10, e0119156.	2.5	41
63	Soluble epoxide hydrolase inhibition improves coronary endothelial function and prevents the development of cardiac alterations in obese insulin-resistant mice. American Journal of Physiology - Heart and Circulatory Physiology, 2015, 308, H1020-H1029.	3.2	44
64	P-179: Impact of the inhibition of soluble epoxide hydrolase on cardiovascular consequences of chronic kidney disease. Annales De Cardiologie Et D'Angeiologie, 2015, 64, S83.	0.6	0
65	Light chain deposition disease and proximal tubulopathy in two successive kidney allografts. Clinical Nephrology, 2015, 83 (2015), 351-356.	0.7	8
66	Impact of soluble epoxide hydrolase inhibition on early kidney damage in hyperglycemic overweight mice. Prostaglandins and Other Lipid Mediators, 2015, 120, 148-154.	1.9	26
67	Pneumocystis jirovecii Pneumonia in Everolimus-Treated Renal Cell Carcinoma. Journal of Clinical Oncology, 2015, 33, e45-e47.	1.6	12
68	Adult-onset renal thrombotic microangiopathy and pulmonary arterial hypertension in cobalamin C deficiency. Lancet, The, 2015, 386, 1011-1012.	13.7	55
69	Polycystin deficiency induces dopamine-reversible alterations in flow-mediated dilatation and vascular nitric oxide release in humans. Kidney International, 2015, 87, 465-472.	5.2	49
70	Editorial (Thematic Issue: Renal Endothelial Dysfunction: Evolving Concepts And Perspectives). Cardiovascular & Hematological Disorders Drug Targets, 2014, 14, 1-2.	0.7	4
71	Subclinical Antibody Mediated Rejection in Kidney Transplantation: Protocol Biopsy for De Novo Donor Specific Antibody, a Single-Center Experience.. Transplantation, 2014, 98, 436.	1.0	0
72	Differential circadian pattern of water and Na excretion rates in the metabolic syndrome. Chronobiology International, 2014, 31, 861-867.	2.0	10

#	Article	IF	Citations
73	Design and discovery of soluble epoxide hydrolase inhibitors for the treatment of cardiovascular diseases. Expert Opinion on Drug Discovery, 2014, 9, 229-243.	5.0	28
74	â€˜Spontaneousâ€™ Subcapsular Hyperdensity of a Postâ€Transplant Kidney Allograft. Nephrology, 2014, 19, 815-815.	1.6	0
75	Monitoring of hemodialysis quality-of-care indicators: why is it important?. BMC Nephrology, 2013, 14, 109.	1.8	13
76	Insuffisance rÃ©nale aiguÃ« obstructiveÂ: le point de vue du rÃ©animateur. ProgrÃ¨s En Urologie - FMC, 2013, 23, F19-F22.	0.1	5
77	Williams-Beuren Syndrome Hypercalcemia: Is TRPC3 a Novel Mediator in Calcium Homeostasis?. Pediatrics, 2012, 129, e1626-e1630.	2.1	43
78	Genetic inhibition of discoidin domain receptor 1 protects mice against crescentic glomerulonephritis. FASEB Journal, 2012, 26, 4079-4091.	0.5	65
79	Recurrent Membranous Nephropathy in an Allograft Caused by IgG3Îº Targeting the PLA2 Receptor. Journal of the American Society of Nephrology: JASN, 2012, 23, 1949-1954.	6.1	94
80	Notchâ€3 receptor activation drives inflammation and fibrosis following tubulointerstitial kidney injury. Journal of Pathology, 2012, 228, 286-299.	4.5	83
81	Identification of Periostin as a Critical Marker of Progression/Reversal of Hypertensive Nephropathy. PLoS ONE, 2012, 7, e31974.	2.5	62
82	Diabetic CVD â€“ Soluble Epoxide Hydrolase as A Target. Cardiovascular and Hematological Agents in Medicinal Chemistry, 2012, 10, 212-222.	1.0	14
83	Progression of renal fibrosis: the underestimated role of endothelial alterations. Fibrogenesis and Tissue Repair, 2012, 5, S15.	3.4	46
84	Discoidin Domain Receptor 1 Is a Major Mediator of Inflammation and Fibrosis in Obstructive Nephropathy. American Journal of Pathology, 2011, 179, 83-91.	3.8	100
85	The role of cell plasticity in progression and reversal of renal fibrosis. International Journal of Experimental Pathology, 2011, 92, 151-157.	1.3	28
86	Reduced Insulin Secretion and Nocturnal Dipping of Blood Pressure Are Associated with a Disturbed Circadian Pattern of Urine Excretion in Metabolic Syndrome. Journal of Clinical Endocrinology and Metabolism, 2011, 96, E929-E933.	3.6	10
87	Determinants of Osteopenia in Male Renal-Stoneâ€“Disease Patients with Idiopathic Hypercalciuria. Clinical Journal of the American Society of Nephrology: CJASN, 2011, 6, 1149-1154.	4.5	53
88	Notch3 Is Essential for Regulation of the Renal Vascular Tone. Hypertension, 2011, 57, 1176-1182.	2.7	49
89	Acute renal failure and Fanconi syndrome due to deferasirox. Nephrology Dialysis Transplantation, 2010, 25, 2376-2378.	0.7	54
90	Podocyte Glutamatergic Signaling Contributes to the Function of the Glomerular Filtration Barrier. Journal of the American Society of Nephrology: JASN, 2009, 20, 1929-1940.	6.1	77

#	Article	IF	Citations
91	Improvement of renal hemodynamics during hypertension-induced chronic renal disease: role of EGF receptor antagonism. American Journal of Physiology - Renal Physiology, 2009, 297, F191-F199.	2.7	17
92	Nephroangiosclerosis in Cerebral Autosomal Dominant Arteriopathy With Subcortical Infarcts and Leukoencephalopathy: Is NOTCH3 Mutation the Common Culprit?. American Journal of Kidney Diseases, 2008, 52, 340-345.	1.9	17
93	Haemodialysis catheterization via type II persistent left superior vena cava. CKJ: Clinical Kidney Journal, 2008, 1, 100-102.	2.9	2
94	Glomerulonephritis with non-Randall-type, non-cryoglobulinemic monoclonal immunoglobulin G deposits [PGNMID and ITG]. CKJ: Clinical Kidney Journal, 0, , .	2.9	0
95	Adequacy between practice and european guidelines on hyponatremia: a survey among french nephrologists. CKJ: Clinical Kidney Journal, 0, , .	2.9	0